The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.

Inclusion Criteria:

• Patient has been diagnosed with Non-infectious intermediate, posterior and pan-uveitis
• Patients voluntarily signed a patient authorization & informed consent form.
• Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study.
• Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines.

Exclusion Criteria:

• A patient who are contraindications to originator adalimumab (Humira®) as listed on the approved Korean label.
• A patient who is participating on other interventional clinical trials
• Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments.

Non-infectious intermediate, posterior and panuveitis (NIIPPU) patients who had been prescribed with Humira® will be registered to the study in accordance with the drug approval status as well as the investigator's clinical judgment.